Showing 8,221 - 8,240 results of 101,552 for search '(( 5 we decrease ) OR ( 5 ((((point decrease) OR (fold decrease))) OR (a decrease)) ))', query time: 1.78s Refine Results
  1. 8221

    Data_Sheet_4_Two DNA Methyltransferases for Site-Specific 6mA and 5mC DNA Modification in Xanthomonas euvesicatoria.PDF by Hye-Jee Park (3594245)

    Published 2021
    “…Xe(XvDMT2) was more tolerant to EtOH than Xe(XvDMT1), which had enhanced tolerance to sorbitol but decreased tolerance to polymyxin B. Using single-molecule real-time sequencing and methylation-sensitive restriction enzymes, we successfully predicted putative motifs methylated by XvDMT1 and XvDMT2, which are previously uncharacterized 6mA and 5mC DNA MTases, respectively. …”
  2. 8222

    Data_Sheet_2_Two DNA Methyltransferases for Site-Specific 6mA and 5mC DNA Modification in Xanthomonas euvesicatoria.pdf by Hye-Jee Park (3594245)

    Published 2021
    “…Xe(XvDMT2) was more tolerant to EtOH than Xe(XvDMT1), which had enhanced tolerance to sorbitol but decreased tolerance to polymyxin B. Using single-molecule real-time sequencing and methylation-sensitive restriction enzymes, we successfully predicted putative motifs methylated by XvDMT1 and XvDMT2, which are previously uncharacterized 6mA and 5mC DNA MTases, respectively. …”
  3. 8223

    Data_Sheet_1_Two DNA Methyltransferases for Site-Specific 6mA and 5mC DNA Modification in Xanthomonas euvesicatoria.PDF by Hye-Jee Park (3594245)

    Published 2021
    “…Xe(XvDMT2) was more tolerant to EtOH than Xe(XvDMT1), which had enhanced tolerance to sorbitol but decreased tolerance to polymyxin B. Using single-molecule real-time sequencing and methylation-sensitive restriction enzymes, we successfully predicted putative motifs methylated by XvDMT1 and XvDMT2, which are previously uncharacterized 6mA and 5mC DNA MTases, respectively. …”
  4. 8224
  5. 8225
  6. 8226

    Data_Sheet_1_Nitrogen and Phosphorus Retranslocation of Leaves and Stemwood in a Mature Eucalyptus Forest Exposed to 5 Years of Elevated CO2.docx by Kristine Y. Crous (6758423)

    Published 2019
    “…Given differences in how N and P are used by plants, we asked if their stoichiometry in leaves and wood was maintained or altered in a long-term elevated CO<sub>2</sub> experiment in a mature Eucalyptus forest on a low P soil (EucFACE). …”
  7. 8227
  8. 8228

    CC genotype of rs7120118 variation associates with decreased soluble Aβ42 levels in the temporal cortex. by Teemu Natunen (398069)

    Published 2013
    “…<p>(A) The distribution of rs7120118 genotypes in subgroups divided by the severity of the disease (mild n = 19/18/9; moderate n = 4/4/5; severe n = 10/12/2, rs7120118 genotypes TT/CT/CC, respectively). …”
  9. 8229
  10. 8230

    Antimycin A treatment decreases respiratory internal rotenone-insensitive NADH oxidation capacity in potato leaves-4 by Daniela A Geisler (70613)

    Published 2011
    “…Black columns, leaves sprayed with 10 μM antimycin A. Transcript abundance is shown for 1 (A), TC54504 (B) and the 28.5 kDa subunit of complex I (C). …”
  11. 8231
  12. 8232
  13. 8233

    DataSheet_1_MiR-199a-5P promotes osteogenic differentiation of human stem cells from apical papilla via targeting IFIT2 in apical periodontitis.pdf by Jing Hu (41899)

    Published 2023
    “…RNA binding protein immunoprecipitation (RIP) and Luciferase reporter assay were conducted to identify the target gene of miR-199a-5p.</p>Results<p>The expression of miR-199a-5p was decreased in the periapical tissues of AP patients, and miR-199a-5p mimics markedly enhanced cell proliferation and osteogenic differentiation of hSCAPs, while miR-199a-5p antagomir dramatically attenuated hSCAPs osteogenesis. …”
  14. 8234
  15. 8235
  16. 8236

    Data_Sheet_2_Efficacy and safety of endothelin receptor antagonists, phosphodiesterase type 5 Inhibitors, and prostaglandins in pediatric pulmonary arterial hypertension: A network... by Fen Cao (4496014)

    Published 2023
    “…To compare the effectiveness and safety of endothelin receptor antagonists (ERAs), phosphodiesterase type 5 Inhibitors (PDE-5i), and prostaglandins (ProA) in the treatment of pediatric PAH, we investigated six hemodynamic parameters, four respiratory parameters, intensive care unit (ICU) stay duration, length of hospital stay, and two safety outcomes.…”
  17. 8237

    Data_Sheet_1_Efficacy and safety of endothelin receptor antagonists, phosphodiesterase type 5 Inhibitors, and prostaglandins in pediatric pulmonary arterial hypertension: A network... by Fen Cao (4496014)

    Published 2023
    “…To compare the effectiveness and safety of endothelin receptor antagonists (ERAs), phosphodiesterase type 5 Inhibitors (PDE-5i), and prostaglandins (ProA) in the treatment of pediatric PAH, we investigated six hemodynamic parameters, four respiratory parameters, intensive care unit (ICU) stay duration, length of hospital stay, and two safety outcomes.…”
  18. 8238

    Data_Sheet_3_Efficacy and safety of endothelin receptor antagonists, phosphodiesterase type 5 Inhibitors, and prostaglandins in pediatric pulmonary arterial hypertension: A network... by Fen Cao (4496014)

    Published 2023
    “…To compare the effectiveness and safety of endothelin receptor antagonists (ERAs), phosphodiesterase type 5 Inhibitors (PDE-5i), and prostaglandins (ProA) in the treatment of pediatric PAH, we investigated six hemodynamic parameters, four respiratory parameters, intensive care unit (ICU) stay duration, length of hospital stay, and two safety outcomes.…”
  19. 8239

    Data_Sheet_4_Efficacy and safety of endothelin receptor antagonists, phosphodiesterase type 5 Inhibitors, and prostaglandins in pediatric pulmonary arterial hypertension: A network... by Fen Cao (4496014)

    Published 2023
    “…To compare the effectiveness and safety of endothelin receptor antagonists (ERAs), phosphodiesterase type 5 Inhibitors (PDE-5i), and prostaglandins (ProA) in the treatment of pediatric PAH, we investigated six hemodynamic parameters, four respiratory parameters, intensive care unit (ICU) stay duration, length of hospital stay, and two safety outcomes.…”
  20. 8240